ライフサイエンスコーパス: poliovirus

1 f the virulent Mahoney strain of wild type 1 poliovirus.

2 major step towards the final eradication of poliovirus.

3 nd dengue virus but not for the nonenveloped poliovirus.

4 serum neutralising antibodies to serotype-3 poliovirus.

5 ollowing interruption of transmission of the poliovirus.

6 ot received any previous vaccination against poliovirus.

7 rgency plan to interrupt the transmission of poliovirus.

8 degree of intestinal immunity against type 2 poliovirus.

9 ) between groups in seroconversion to type-1 poliovirus.

10 ulations that have low levels of immunity to poliovirus.

11 accine-derived poliomyelitis from serotype 2 poliovirus.

12 th America since the regional eradication of poliovirus.

13 alytic polio and circulating vaccine-derived poliovirus.

14 art of a crucial strategy for containment of polioviruses.

15 ne-derived polioviruses (cVDPV2) and 14 wild polioviruses.

16 uce risks of re-emergence of vaccine-derived polioviruses.

17 al to stop the circulation of remaining wild polioviruses.

18 eroconversion for type 1, type 2, and type 3 polioviruses.

19 eracruz, Mexico, revealed no vaccine-derived polioviruses.

20 ion certified the eradication of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing par

21 nally, we show that cleavage of eIF4G by the poliovirus 2A protease generates a high-affinity IRES bi

22 Poliovirus 2C(ATPase) has important roles both in RNA re

23 in 2C(ATPase) In particular, residue N252 of poliovirus 2C(ATPase) interacts with VP3 of coxsackievir

24 this study, we have searched for residues in poliovirus 2C(ATPase), near a presumed capsid-interactin

25 ge site within G3BP1, which differs from the poliovirus 3C proteinase cleavage site previously identi

26 We previously showed that poliovirus 3C proteinase cleaves the SG-nucleating prote

27 version and median antibody titres to type 2 poliovirus 4 weeks after vaccination with mIPV2HD or IPV

28 imary outcomes were seroprevalence rates for poliovirus 4-6 weeks post-vaccination and the rate of se

29 e how different bacteria impact infection of poliovirus, a model enteric virus.

30 cting the establishment of the resistance of poliovirus, a small (+)RNA virus, to brefeldin A (BFA),

31 both attenuated (Sabin strain) and wild-type polioviruses, a finding that should greatly facilitate g

32 orm a mathematical model to demonstrate that poliovirus adapts most rapidly at an optimal mutation ra

33 s on re-introduction or resurgence of type 2 poliovirus after this switch is not understood completel

34 perties indistinguishable from those of wild poliovirus and can cause paralytic disease.

35 Enteroviruses such as poliovirus and coxsackievirus recruit PI4KIIIbeta to the

36 s identified that, upon silencing, increased poliovirus and enterovirus 71 production by from 10-fold

37 The molecular interactions we see between poliovirus and its receptor are reminiscent of the necti

38 own that the specificity of encapsidation of poliovirus and of C-cluster coxsackieviruses, which are

39 Structures of the expanded forms of poliovirus and of several related viruses have recently

40 ities for immunization activities (including poliovirus and other vaccines) and other health benefits

41 program will be the complete eradication of poliovirus and the elimination of polio for all time.

42 ion of RNA-containing viruses, starting with poliovirus and then moving to vesicular stomatitis virus

43 units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals.

44 serum neutralising antibodies to serotype-3 poliovirus at a dilution of one in eight or more on day

45 izing VHHs with the Mahoney strain of type 1 poliovirus at resolutions ranging from 3.8 to 6.3A.

46 d the potential circulation of imported live polioviruses before globally coordinated cessation of OP

47 The structures of poliovirus bound to single-domain antibodies presented h

48 ructurally from canonical Type 1 IRESs (e.g. poliovirus) but nevertheless also contains an essential

49 confirm suppression of hepatitis B virus and poliovirus by ARB.

50 s) to bivalent OPV (containing types 1 and 3 poliovirus) called for intense global communications and

51 e of writing, only 3 countries in which wild poliovirus circulation has never been interrupted remain

52 ood effect, as evidenced by the reduction of poliovirus circulation in Kano.

53 ntrywide environmental surveillance, no wild poliovirus circulation was detected between 1989 and Feb

54 group, 175 (50%) seroconverted to serotype-3 poliovirus compared with 192 (54%) in the placebo group

55 polio vaccines (OPVs), starting with type 2 poliovirus-containing vaccine and introduction of inacti

56 est detection of circulating vaccine-derived poliovirus (cVDPV) is 300 days for Sabin-like virus type

57 elated to type 2-circulating vaccine-derived poliovirus (cVDPV2).

58 , ES reported 97 circulating vaccine-derived polioviruses (cVDPV2) and 14 wild polioviruses.

59 e is eliminating circulating vaccine-derived polioviruses (cVDPVs) that have properties indistinguish

60 the emergence of circulating vaccine-derived polioviruses (cVDPVs).

61 in a subdomain (d10c) that is homologous to poliovirus dIVc.

62 iruses) to bivalent OPV (bOPV; types 1 and 3 polioviruses) during a 2-week period in April 2016.

63 s variants by deep sequencing may aid in the poliovirus endgame and efforts to ensure global polio er

64 d Health Assembly declared the completion of poliovirus eradication a programmatic emergency for glob

65 s quality control agents for the end game of poliovirus eradication are discussed.

66 Global poliovirus eradication efforts include high vaccination

67 012, the WHA declared that the completion of poliovirus eradication is a programmatic emergency for g

68 However, poliovirus eradication is hampered globally by epidemics

69 nation may help mankind achieve and maintain poliovirus eradication.

70 Importantly, poliovirus expansion is regulated by the binding of a li

71 e efforts could have contributed to the wild poliovirus-free 2-year period between 24 July 2014 and 1

72 roughout the non-structural coding region of poliovirus from dually transfected cells.

73 Elimination of poliovirus from endemic countries is a crucial step in e

74 Eradication of poliovirus from endemic countries relies on vaccination

75 Despite success in eliminating wild poliovirus from most of the world, polio persists in pop

76 interventions that followed the isolation of polioviruses from ES between 2012 and 2015.

77 ainty about whether or not all types of wild polioviruses had been eradicated, but it might increase

78 eria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine; age 6/

79 However, because wild-type 2 poliovirus has been eradicated, the World Health Organiz

80 ndings give us a better understanding of how poliovirus has evolved to exploit a natural process of i

81 Cases of paralysis caused by poliovirus have decreased by >99% since the 1988 World H

82 polio vaccines (OPVs) once all types of wild polioviruses have been eradicated.

83 RNA viruses, such as poliovirus, have a great evolutionary capacity, allowing

84 e barriers to infection.RNA viruses, such as polioviruses, have a great evolutionary capacity and can

85 Here, we report poliovirus in complex with an enzymatically partially de

86 of poliomyelitis associated with wild-type 1 poliovirus in districts of Pakistan over 6-month interva

87 ns of circulating serotype 2 vaccine-derived poliovirus in northern Nigeria (Borno and Sokoto states)

88 n (Balochistan Province) and serotype 1 wild poliovirus in Pakistan, Afghanistan, and Nigeria (Borno)

89 myelitis certified the eradication of type 2 poliovirus in September 2015, making type 2 poliovirus t

90 ortions of children seroconverting to type 2 poliovirus in the IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-I

91 dentified environmental surveillance (ES) of poliovirus in the poliomyelitis eradication strategic pl

92 Estimated movement of poliovirus-infected individuals was associated with the

93 Because the model recapitulates human poliovirus infection and poliomyelitis, it can be used t

94 Because the model recapitulates human poliovirus infection and poliomyelitis, it can be used t

95 whole-genome sequences and information about poliovirus infection dynamics and the individual vaccina

96 Here we show that poliovirus infection in immune-competent mice requires a

97 Here, the authors show that poliovirus infection in mice requires adaptation to inna

98 rations was presumed to favor the widespread poliovirus infection in Pakistan.

99 Poliovirus infection is initiated by attachment to a rec

100 ccines.IMPORTANCE Early pathogenic events of poliovirus infection remain largely undefined, and there

101 the early pathogenic events in natural oral poliovirus infection remain poorly defined.

102 operational challenges, with no case of wild poliovirus infection since July 2014.

103 When poliovirus infects a cell, it undergoes a change in its

104 Our results, of both poliovirus intertypic and intratypic recombination in th

105 uced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof wi

106 PCBP2 has three KH domains and binds poliovirus IRES domain dIV in the vicinity of the tetral

107 ating the risk of polio from vaccine-derived polioviruses is essential for creating a polio-free worl

108 imized whole-genome sequencing protocols for poliovirus isolates and FTA cards using next-generation

109 first to combine whole-genome sequencing of poliovirus isolates collected during routine surveillanc

110 we studied molecular evolution in Sabin-like poliovirus isolates from Nigerian acute flaccid paralysi

111 plementary technical and support capacities (poliovirus isolation, molecular strain characterization

112 After 2 years without reporting any wild poliovirus (July 2014-2016), the region undertook the sy

113 de insights into several other stages of the poliovirus life cycle, including the mechanism of recept

114 deficiencies who can excrete vaccine-derived poliovirus long-term.

115 Moreover, the BFA resistance phenotype of poliovirus mutants is also cell type dependent in differ

116 ng method demonstrated reliable detection of poliovirus mutations at levels of <1%, depending on read

117 ered intradermally to induce levels of serum poliovirus-neutralizing antibodies similar to immunizati

118 Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccine

119 rotein, five were present in neuropathogenic poliovirus or enterovirus D70, or both.

120 The risk of transmission of type 2 poliovirus or Sabin 2 virus on re-introduction or resurg

121 capsid protein(s) and replication proteins (poliovirus), or (b) by the high affinity interaction of

122 During the poliovirus outbreak in Cameroon from October 2013 to Apr

123 By studying the emergence of vaccine-derived poliovirus outbreaks, Stern et al. describe how a combin

124 tire viral genome" play the critical role in poliovirus packaging specificity.

125 ning viremia), extending previous studies of poliovirus pathogenesis in humans.

126 supplementing historical reconstructions of poliovirus pathogenesis.

127 y, we examined the structure and function of poliovirus polymerase, 3D(pol), as it relates to RNA rec

128 Similar modulation effects are seen in poliovirus polymerase, an inherently lower-fidelity enzy

129 the structure and mutation distribution of a poliovirus population in an intact single infected cell.

130 er identify a region in the multi-functional poliovirus protein 2B as a hotspot for the accumulation

131 fashion and also blocked the replication of poliovirus (PV) and foot-and-mouth disease virus (FMDV)

132 ive since 1988, by isolating and identifying poliovirus (PV) from stool specimens by using cell cultu

133 d increases the rate of restructuring of the poliovirus (PV) IRES.

134 The poliovirus (PV) is currently targeted for worldwide erad

135 Poliovirus (PV) is the causative agent of poliomyelitis,

136 ruses, which include coxsackievirus B (CVB), poliovirus (PV), and enterovirus 71 (EV71), co-opt the h

137 tis is a highly infectious disease caused by poliovirus (PV).

138 Here, we have used (31)P NMR with poliovirus RdRp to show that the binding environment of

139 The poliovirus receptor (PVR) is a ubiquitously expressed gl

140 ULBP)1-6 (NKG2D ligand), Nectin-2/CD112, and poliovirus receptor (PVR)/CD155 (DNAM-1 ligand), are oft

141 using transgenic mouse expressing the human poliovirus receptor (Tg21-PVR) mice, and their antigenic

142 canyon at sites that extensively overlap the poliovirus receptor-binding site.

143 nsertional mutagenesis screen, we identified poliovirus receptor-like 3 (PVRL3) as a cellular factor

144 ne response in mice transgenic for the human poliovirus receptor.

145 mbinants with known Nigerian vaccine-derived poliovirus recombinants shows that while recombination w

146 We identified a poliovirus recombination determinant within the virus po

147 tudies provide the basis for the analysis of poliovirus recombination throughout the non-structural r

148 Protection against poliovirus remained elevated 6 and 11 months after an IP

149 ly, silencing of several genes that enhanced poliovirus replication also enhanced replication of ente

150 Identification of mechanisms that limit poliovirus replication is crucial for informing decision

151 trates that early in the infectious process, poliovirus replication occurs in both epithelial cells (

152 trates that early in the infectious process, poliovirus replication occurs in both epithelial cells (

153 identify gene knockdown events that enhanced poliovirus replication.

154 tial inhibition of Influenza A virus-but not poliovirus-replication in human cells.

155 mucosal immunity and allow estimation of the poliovirus reservoir.

156 We investigated here the development of poliovirus resistance to brefeldin A (BFA), an inhibitor

157 Measles and poliovirus responses were unaffected (measles, 6.8% [95%

158 say in which the only protein present is the poliovirus RNA dependent RNA polymerase (RdRp), which re

159 We found that DNase treatment of poliovirus RNA followed by random reverse transcription

160 sis with a non-inferiority margin of 10% for poliovirus seroprevalence and measles, rubella, and yell

161 Poliovirus seroprevalence was universally high (>97%) af

162 though it results in a high post-vaccination poliovirus seroprevalence.

163 fected (measles, 6.8% [95% CI -1.4 to 14.9]; poliovirus serotype 1, 1.6% [-6.7 to 4.7]; serotype 2, 0

164 dy titres (within two-thirds log2 titres) to poliovirus serotypes 1 and 3 at age 28 weeks, analysed i

165 us vaccine and oral polio vaccine containing poliovirus serotypes 1 and 3 were all significantly high

166 eline immunity was 87%, 90%, and 66% against poliovirus serotypes 1, 2, and 3, respectively.

167 ation of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the b

168 Assembly (WHA) resolved in 1988 to eradicate poliovirus, several rounds of immunization campaigns hav

169 Poliovirus shedding 7 days after challenge was less prev

170 The primary outcome was poliovirus shedding in stool 7 days after bivalent OPV c

171 9 and February 2013, after which wild type 1 polioviruses South Asia genotype (WPV1-SOAS) have persis

172 ose that population genetic dynamics enables poliovirus spread between tissues through optimization o

173 Phylogenetic analysis suggests that wild poliovirus strains from endemic regions were genetically

174 ing cell line using attenuated and wild-type poliovirus strains.

175 om FTA cards will aid in facilitating global poliovirus surveillance.

176 ss stabilized virus-like particles of type 3 poliovirus that can induce a protective immune response

177 poliovirus in September 2015, making type 2 poliovirus the first human pathogen to be eradicated sin

178 The eradication of type 2 poliovirus, the absence of detection of type 3 polioviru

179 ient individuals who excrete vaccine-derived polioviruses threaten polio eradication.

180 bivalent OPV (bOPV; containing types 1 and 3 poliovirus), thus withdrawing OPV2.

181 gle and dual gene silencing events increased poliovirus titers >20-fold and >50-fold, respectively.

182 de since November 2012, and cornering type 1 poliovirus to only a few geographic areas of 3 countries

183 th knowledge about the intrahost dynamics of poliovirus to provide quantitative insight into polio va

184 rapidly increase population immunity against polioviruses to control outbreaks or prevent transmissio

185 lent OPV (tOPV; containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 an

186 trivalent OPV (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containing types 1 and 3 po

187 from trivalent OPV (tOPV; types 1, 2, and 3 polioviruses) to bivalent OPV (bOPV; types 1 and 3 polio

188 ors and movement patterns that contribute to poliovirus transmission across Pakistan would support ev

189 ed subpopulations, using an existing dynamic poliovirus transmission and oral poliovirus vaccine evol

190 tion-based model to simulate the dynamics of poliovirus transmission and population immunity in Israe

191 enges in eradicating polio due to widespread poliovirus transmission and security challenges.

192 Even though poliovirus transmission has not yet been stopped globall

193 However endemic wild poliovirus transmission in Nigeria, Pakistan, and Afghan

194 that have contributed to the interruption of poliovirus transmission in Nigeria.

195 also investigated with a dynamical model of poliovirus transmission to observe prevalence and incide

196 mical synthesis generated viable variants of poliovirus type 1 (PV1), whose ORF (6,189 nucleotides) c

197 tion, we analyzed the virologic data of wild poliovirus type 1 (WPV1) strains detected in Pakistan du

198 Nanobodies, or VHHs, that recognize poliovirus type 1 have previously been selected and char

199 adults were challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently treat

200 n in selected areas at risk for emergence of poliovirus type 2 during the next phase of the polio era

201 of a novel monovalent high-dose inactivated poliovirus type 2 vaccine (mIPV2HD) in infants.

202 ation with mIPV2HD or IPV, seroconversion to poliovirus type 2 was recorded in 107 (93.0%, 95% CI 86.

203 <0.0001), and median antibody titres against poliovirus type 2 were 181 (95% CI 72.0-362.0) in the mI

204 PV after IPV boosted intestinal immunity for poliovirus type 2, suggesting possible cross protection.

205 ill be the only source of protection against poliovirus type 2.

206 dels were developed for two viruses, MS2 and poliovirus type 3; laboratory- and field-scale experimen

207 Seroconversion to each poliovirus type was seen in 100% of rats that received

208 Neutralising activity and poliovirus type-specific IgA were measured in stool afte

209 Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in s

210 g the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was already high for the th

211 The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with titres more than or eq

212 e values were greater (91%, 87%, and 85% for poliovirus types 1, 2, and 3, respectively).In 2013, the

213 roprevalence values of 81%, 75%, and 73% for poliovirus types 1, 2, and 3, respectively, among infant

214 of fIPV recipients had an immune response to poliovirus types 1, 2, and 3, respectively, compared wit

215 ints, optimisation of protection against all poliovirus types will be a priority of the global eradic

216 Seroconversion rates against polioviruses types 1 and 3 were non-inferior in sequenti

217 provides molecular epidemiological data from polioviruses used to inform programmatic and immunizatio

218 cine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) and global introduction of ina

219 Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to

220 A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intraderma

221 ractional-dose administration of inactivated poliovirus vaccine (fIPV) could increase IPV affordabili

222 0.1 mL) intradermal doses of the inactivated poliovirus vaccine (ID fIPV) is positively correlated wi

223 aptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the

224 es with experience in the use of inactivated poliovirus vaccine (IPV) are important for the global po

225 bOPV) and global introduction of inactivated poliovirus vaccine (IPV) are major steps in the polio en

226 In 2014, 2 studies showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in c

227 e ability of fractional doses of inactivated poliovirus vaccine (IPV) delivered intradermally to indu

228 oduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunisation program

229 ation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination progra

230 The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in th

231 h vaccination coverage with only inactivated poliovirus vaccine (IPV) since 2005.

232 ypes 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of prot

233 n of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV

234 the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual i

235 ber of newborns given the first dose of oral poliovirus vaccine (OPV) according to the RI schedule an

236 epitope-specific monoclonal murine anti-oral poliovirus vaccine (OPV) antibodies, and sera from IPV-i

237 he live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially,

238 del expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV2) ce

239 immunisation activities with different oral poliovirus vaccine (OPV) formulations, and serotype-spec

240 due to past exposure to WPV and use of oral poliovirus vaccine (OPV) in addition to IPV.

241 Withdrawal of type 2 oral poliovirus vaccine (OPV) in OPV-using countries required

242 Trivalent oral poliovirus vaccine (OPV) is known to interfere with mono

243 irus vaccine in all 126 countries using oral poliovirus vaccine (OPV) only as of 2012, (2) full withd

244 cularly, among adults with a history of oral poliovirus vaccine (OPV) receipt.

245 a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be repl

246 y in children previously immunized with oral poliovirus vaccine (OPV).

247 compare the safety profiles of IPV and oral poliovirus vaccine (OPV).

248 Global withdrawal of serotype-2 oral poliovirus vaccine (OPV2) took place in April 2016.

249 roposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV

250 Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 or

251 d regulatory approval for use of inactivated poliovirus vaccine and bivalent OPV in routine immunizat

252 ces in approach observed between inactivated poliovirus vaccine and bivalent OPV.

253 fied an analysis censoring follow-up at oral poliovirus vaccine campaigns.

254 ion (0.66; .44-1.00) when censoring for oral poliovirus vaccine campaigns.

255 Oral poliovirus vaccine can mutate to regain neurovirulence.

256 (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery.

257 n did not improve the immunogenicity of oral poliovirus vaccine despite reducing biomarkers of enviro

258 ing dynamic poliovirus transmission and oral poliovirus vaccine evolution model.

259 immunogenicity of serotype-3 monovalent oral poliovirus vaccine given to healthy infants living in 14

260 or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).

261 ssess whether antibiotics would improve oral poliovirus vaccine immunogenicity.

262 arned during the introduction of inactivated poliovirus vaccine in 3 countries that would make future

263 (1) introduction of >/=1 dose of inactivated poliovirus vaccine in all 126 countries using oral polio

264 ss the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular evolu

265 Oral poliovirus vaccine is less immunogenic and effective in

266 days, followed by serotype-3 monovalent oral poliovirus vaccine on day 14.

267 Mass vaccination campaigns with the oral poliovirus vaccine targeting children aged <5 years are

268 ed 9-10 months who had already received oral poliovirus vaccine were randomly assigned to receive the

269 e who received azithromycin or placebo, oral poliovirus vaccine, and provided a blood sample accordin

270 eived the third dose of pentavalent and oral poliovirus vaccine, respectively, but only 65% received

271 ype 2 component, introduction of inactivated poliovirus vaccine, strengthening of routine immunizatio

272 tate polio eradication using the inactivated poliovirus vaccine.

273 dule of ages 6 and 10 weeks, along with oral poliovirus vaccine.

274 ntually need to be replaced with inactivated poliovirus vaccines (IPV).

275 plementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by 4 we

276 synthesize stable VLPs as future genome-free poliovirus vaccines.

277 est that monitoring emerging vaccine-related poliovirus variants by deep sequencing may aid in the po

278 nomic region to characterize vaccine-related poliovirus variants.

279 PVs, especially for those in vaccine-derived polioviruses (VDPV), circulating VDPV, or immunodeficien

280 uent outbreaks of serotype-2 vaccine-derived polioviruses (VDPV2s).

281 The emergence of vaccine-derived polioviruses (VDPVs), however, remains a risk, as oral p

282 ed circulation of serotype 2 vaccine-derived polioviruses (VDPVs).

283 cryo-electron microscopy, expanded 80S-like poliovirus virions (poliovirions) were visualized in com

284 Seroconversion for type-1 poliovirus was recorded in 183 (98%, 95% CI 95-100) of 1

285 Proportions of seroconversion to type-1 poliovirus were 107/135 (79%, 95% CI 72.4-86.1) with mOP

286 Proportions with seroconvsion to type 3 poliovirus were 163 (98.2%) of 166, 94.8-99.4; 177 (100%

287 Proportions to type 3 poliovirus were 166 (98.2%) of 169, 94.9-99.4; 180 (100%

288 ns of children with seroconversion to type 1 poliovirus were 166 (98.8%) of 168, 95% CI 95.8-99.7; 17

289 ith seroprotective antibody titres to type 1 poliovirus were 168 (98.8%) of 170, 95% CI 95.8-99.7; 18

290 c analysis showed that EVs of the C species (polioviruses) were associated with the post-polio syndro

291 wed decreased replicative permissiveness for poliovirus, which also replicates in double-membrane ves

292 cryo-electron microscopy reconstructions of poliovirus with five neutralizing VHHs.

293 extracted from cecal contents of mice, bound poliovirus, with each bacterium binding multiple virions

294 liovirus, the absence of detection of type 3 poliovirus worldwide since November 2012, and cornering

295 Anticipating the eradication of wild poliovirus (WPV) and the subsequent challenges in preven

296 e monitoring paid off, as the number of wild poliovirus (WPV) cases detected in Nigeria were reduced

297 Despite a 99% reduction in annual wild poliovirus (WPV) cases since 1988, tackling the last 1%

298 liomyelitis cases caused by circulating wild poliovirus (WPV) in Israel, sewage sampling detected WPV

299 strategies to curb the transmission of wild poliovirus (WPV) in the country.

300 countries that had already interrupted wild poliovirus (WPV) transmission, compared with findings fo